2016 Q1 Form 10-Q Financial Statement
#000156459016019580 Filed on May 16, 2016
Income Statement
Concept | 2016 Q1 | 2015 Q1 |
---|---|---|
Revenue | $6.562M | $7.216M |
YoY Change | -9.06% | 21.81% |
Cost Of Revenue | $2.772M | $2.711M |
YoY Change | 2.25% | 25.39% |
Gross Profit | $3.790M | $4.505M |
YoY Change | -15.87% | 19.75% |
Gross Profit Margin | 57.76% | 62.43% |
Selling, General & Admin | $7.413M | $4.728M |
YoY Change | 56.79% | 44.63% |
% of Gross Profit | 195.59% | 104.95% |
Research & Development | $3.159M | $1.421M |
YoY Change | 122.31% | 97.36% |
% of Gross Profit | 83.35% | 31.54% |
Depreciation & Amortization | $261.0K | $165.0K |
YoY Change | 58.18% | 55.66% |
% of Gross Profit | 6.89% | 3.66% |
Operating Expenses | $13.13M | $8.607M |
YoY Change | 52.56% | 39.93% |
Operating Profit | -$6.569M | -$1.391M |
YoY Change | 372.25% | 512.78% |
Interest Expense | $266.0K | $827.0K |
YoY Change | -67.84% | -250.36% |
% of Operating Profit | ||
Other Income/Expense, Net | -$2.917M | -$54.00K |
YoY Change | 5301.85% | -89.79% |
Pretax Income | -$9.752M | -$2.270M |
YoY Change | 329.6% | 74.62% |
Income Tax | $0.00 | |
% Of Pretax Income | ||
Net Earnings | -$9.752M | -$2.272M |
YoY Change | 329.23% | 74.23% |
Net Earnings / Revenue | -148.61% | -31.49% |
Basic Earnings Per Share | -$0.81 | -$0.19 |
Diluted Earnings Per Share | -$0.81 | -$0.19 |
COMMON SHARES | ||
Basic Shares Outstanding | 11.97M | 11.81M |
Diluted Shares Outstanding | 11.97M | 11.81M |
Balance Sheet
Concept | 2016 Q1 | 2015 Q1 |
---|---|---|
SHORT-TERM ASSETS | ||
Cash & Short-Term Investments | $23.80M | $39.00M |
YoY Change | -38.97% | 712.5% |
Cash & Equivalents | $23.75M | $38.99M |
Short-Term Investments | ||
Other Short-Term Assets | $800.0K | $700.0K |
YoY Change | 14.29% | -61.11% |
Inventory | $600.0K | $775.0K |
Prepaid Expenses | ||
Receivables | $2.500M | $1.800M |
Other Receivables | $0.00 | $0.00 |
Total Short-Term Assets | $27.70M | $42.30M |
YoY Change | -34.52% | 345.27% |
LONG-TERM ASSETS | ||
Property, Plant & Equipment | $2.300M | $2.174M |
YoY Change | 5.8% | 44.93% |
Goodwill | $12.01M | |
YoY Change | ||
Intangibles | $6.650M | |
YoY Change | ||
Long-Term Investments | ||
YoY Change | ||
Other Assets | $20.00K | $0.00 |
YoY Change | -100.0% | |
Total Long-Term Assets | $21.13M | $20.98M |
YoY Change | 0.75% | 1211.0% |
TOTAL ASSETS | ||
Total Short-Term Assets | $27.70M | $42.30M |
Total Long-Term Assets | $21.13M | $20.98M |
Total Assets | $48.83M | $63.28M |
YoY Change | -22.83% | 470.06% |
SHORT-TERM LIABILITIES | ||
YoY Change | ||
Accounts Payable | $2.536M | $1.371M |
YoY Change | 84.97% | 71.38% |
Accrued Expenses | $7.100M | $3.400M |
YoY Change | 108.82% | 112.5% |
Deferred Revenue | ||
YoY Change | ||
Short-Term Debt | $0.00 | $0.00 |
YoY Change | ||
Long-Term Debt Due | $4.400M | $1.056M |
YoY Change | 316.67% | -80.8% |
Total Short-Term Liabilities | $14.20M | $6.275M |
YoY Change | 126.29% | -40.8% |
LONG-TERM LIABILITIES | ||
Long-Term Debt | $11.37M | $14.61M |
YoY Change | -22.18% | 37.82% |
Other Long-Term Liabilities | $2.800M | $28.00K |
YoY Change | 9900.0% | -99.58% |
Total Long-Term Liabilities | $11.37M | $14.64M |
YoY Change | -22.33% | -14.9% |
TOTAL LIABILITIES | ||
Total Short-Term Liabilities | $14.20M | $6.275M |
Total Long-Term Liabilities | $11.37M | $14.64M |
Total Liabilities | $28.37M | $23.81M |
YoY Change | 19.17% | -14.35% |
SHAREHOLDERS EQUITY | ||
Retained Earnings | -$182.8M | -$161.6M |
YoY Change | 13.11% | |
Common Stock | $12.00K | $12.00K |
YoY Change | 0.0% | |
Preferred Stock | ||
YoY Change | ||
Treasury Stock (at cost) | ||
YoY Change | ||
Treasury Stock Shares | ||
Shareholders Equity | $20.46M | $39.47M |
YoY Change | ||
Total Liabilities & Shareholders Equity | $48.83M | $63.28M |
YoY Change | -22.83% | 470.06% |
Cashflow Statement
Concept | 2016 Q1 | 2015 Q1 |
---|---|---|
OPERATING ACTIVITIES | ||
Net Income | -$9.752M | -$2.272M |
YoY Change | 329.23% | 74.23% |
Depreciation, Depletion And Amortization | $261.0K | $165.0K |
YoY Change | 58.18% | 55.66% |
Cash From Operating Activities | -$6.190M | -$1.010M |
YoY Change | 512.87% | -661.11% |
INVESTING ACTIVITIES | ||
Capital Expenditures | $109.0K | $364.0K |
YoY Change | -70.05% | 1815.79% |
Acquisitions | ||
YoY Change | ||
Other Investing Activities | ||
YoY Change | ||
Cash From Investing Activities | -$110.0K | -$360.0K |
YoY Change | -69.44% | 1700.0% |
FINANCING ACTIVITIES | ||
Cash Dividend Paid | ||
YoY Change | ||
Common Stock Issuance & Retirement, Net | ||
YoY Change | ||
Debt Paid & Issued, Net | ||
YoY Change | ||
Cash From Financing Activities | 170.0K | 3.930M |
YoY Change | -95.67% | -973.33% |
NET CHANGE | ||
Cash From Operating Activities | -6.190M | -1.010M |
Cash From Investing Activities | -110.0K | -360.0K |
Cash From Financing Activities | 170.0K | 3.930M |
Net Change In Cash | -6.130M | 2.560M |
YoY Change | -339.45% | -982.76% |
FREE CASH FLOW | ||
Cash From Operating Activities | -$6.190M | -$1.010M |
Capital Expenditures | $109.0K | $364.0K |
Free Cash Flow | -$6.299M | -$1.374M |
YoY Change | 358.44% | -953.42% |
Facts In Submission
Frame | Concept Type | Concept / XBRL Key | Value | Unit |
---|---|---|---|---|
CY2016Q1 | us-gaap |
Long Term Debt Noncurrent
LongTermDebtNoncurrent
|
11368000 | |
CY2015Q4 | us-gaap |
Long Term Debt Noncurrent
LongTermDebtNoncurrent
|
12887000 | |
CY2016Q1 | us-gaap |
Accounts Receivable Net
AccountsReceivableNet
|
2512000 | |
CY2016Q1 | us-gaap |
Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
|
147000 | |
CY2016Q1 | us-gaap |
Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
|
735000 | |
CY2016Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
3159000 | |
CY2015Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
1421000 | |
CY2016Q1 | us-gaap |
Selling And Marketing Expense
SellingAndMarketingExpense
|
1737000 | |
CY2015Q1 | us-gaap |
Selling And Marketing Expense
SellingAndMarketingExpense
|
2023000 | |
CY2015Q1 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
2705000 | |
CY2016Q1 | us-gaap |
Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
|
-213000 | |
CY2016Q1 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
20000 | |
CY2016Q1 | us-gaap |
Assets
Assets
|
48834000 | |
CY2016Q1 | us-gaap |
Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
|
5298000 | |
CY2016Q1 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
2536000 | |
CY2016Q1 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
1609000 | |
CY2016Q1 | us-gaap |
Accrued Royalties Current
AccruedRoyaltiesCurrent
|
232000 | |
CY2016Q1 | us-gaap |
Deferred Revenue Current
DeferredRevenueCurrent
|
137000 | |
CY2015Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-173082000 | |
CY2016Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
20460000 | |
CY2015Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
10000000 | |
CY2015Q4 | us-gaap |
Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
|
948000 | |
CY2015Q4 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
28000 | |
CY2016Q1 | us-gaap |
Liabilities
Liabilities
|
28374000 | |
CY2015Q4 | us-gaap |
Liabilities
Liabilities
|
26144000 | |
CY2016Q1 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
CY2015Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
CY2016Q1 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
0 | |
CY2015Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
0 | |
CY2016Q1 | us-gaap |
Common Stock Value
CommonStockValue
|
12000 | |
CY2015Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
12000 | |
CY2016Q1 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
203284000 | |
CY2015Q4 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
202564000 | |
CY2016Q1 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-182836000 | |
CY2015Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
29494000 | |
CY2016Q1 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
48834000 | |
CY2015Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
55638000 | |
CY2016Q1 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.001 | |
CY2015Q4 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.001 | |
CY2016Q1 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
10000000 | |
CY2016Q1 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | |
CY2015Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | |
CY2016Q1 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | |
CY2015Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | |
CY2016Q1 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
CY2015Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
CY2016Q1 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
100000000 | |
CY2015Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
100000000 | |
CY2016Q1 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
11977491 | |
CY2015Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
11902363 | |
CY2016Q1 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
11977491 | |
CY2015Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
11902363 | |
CY2016Q1 | us-gaap |
Sales Revenue Services Net
SalesRevenueServicesNet
|
6452000 | |
CY2015Q1 | us-gaap |
Sales Revenue Services Net
SalesRevenueServicesNet
|
7096000 | |
CY2016Q1 | us-gaap |
License And Services Revenue
LicenseAndServicesRevenue
|
110000 | |
CY2015Q1 | us-gaap |
License And Services Revenue
LicenseAndServicesRevenue
|
120000 | |
CY2016Q1 | us-gaap |
Revenues
Revenues
|
6562000 | |
CY2015Q1 | us-gaap |
Revenues
Revenues
|
7216000 | |
CY2016Q1 | us-gaap |
Cost Of Services
CostOfServices
|
2772000 | |
CY2015Q1 | us-gaap |
Cost Of Services
CostOfServices
|
2711000 | |
CY2016Q1 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
5676000 | |
CY2015Q1 | us-gaap |
Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
|
-253000 | |
CY2016Q1 | us-gaap |
Operating Expenses
OperatingExpenses
|
13131000 | |
CY2015Q1 | us-gaap |
Operating Expenses
OperatingExpenses
|
8607000 | |
CY2016Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-6569000 | |
CY2015Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-1391000 | |
CY2016Q1 | us-gaap |
Interest Expense
InterestExpense
|
266000 | |
CY2015Q1 | us-gaap |
Interest Expense
InterestExpense
|
827000 | |
CY2016Q1 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
-2917000 | |
CY2015Q1 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
-54000 | |
CY2016Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-9752000 | |
CY2015Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-2272000 | |
CY2016Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.81 | |
CY2015Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.19 | |
CY2016Q1 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
11969714 | |
CY2015Q1 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
11814467 | |
CY2016Q1 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
261000 | |
CY2015Q1 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
165000 | |
CY2016Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
446000 | |
CY2015Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
280000 | |
CY2016Q1 | cdna |
Amortization Of Deferred Revenue
AmortizationOfDeferredRevenue
|
16000 | |
CY2015Q1 | cdna |
Amortization Of Deferred Revenue
AmortizationOfDeferredRevenue
|
29000 | |
CY2016Q1 | us-gaap |
Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
|
41000 | |
CY2015Q1 | us-gaap |
Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
|
407000 | |
CY2016Q1 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
145000 | |
CY2015Q1 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
-893000 | |
CY2016Q1 | us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
-171000 | |
CY2015Q1 | us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
88000 | |
CY2016Q1 | us-gaap |
Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
|
-563000 | |
CY2015Q1 | us-gaap |
Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
|
180000 | |
CY2016Q1 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
820000 | |
CY2015Q1 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
242000 | |
CY2016Q1 | us-gaap |
Increase Decrease In Accrued Salaries
IncreaseDecreaseInAccruedSalaries
|
-758000 | |
CY2015Q1 | us-gaap |
Increase Decrease In Accrued Salaries
IncreaseDecreaseInAccruedSalaries
|
-389000 | |
CY2016Q1 | us-gaap |
Increase Decrease In Royalties Payable
IncreaseDecreaseInRoyaltiesPayable
|
-10000 | |
CY2015Q1 | us-gaap |
Increase Decrease In Royalties Payable
IncreaseDecreaseInRoyaltiesPayable
|
14000 | |
CY2016Q1 | us-gaap |
Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
|
2400000 | |
CY2015Q1 | us-gaap |
Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
|
196000 | |
CY2016Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
-6192000 | |
CY2015Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
-1014000 | |
CY2016Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
109000 | |
CY2015Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
364000 | |
CY2016Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
-109000 | |
CY2015Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
-364000 | |
CY2015Q1 | us-gaap |
Proceeds From Debt Net Of Issuance Costs
ProceedsFromDebtNetOfIssuanceCosts
|
15625000 | |
CY2016Q1 | us-gaap |
Proceeds From Stock Plans
ProceedsFromStockPlans
|
175000 | |
CY2016Q1 | us-gaap |
Repayments Of Long Term Debt And Capital Securities
RepaymentsOfLongTermDebtAndCapitalSecurities
|
16000 | |
CY2015Q1 | us-gaap |
Repayments Of Long Term Debt And Capital Securities
RepaymentsOfLongTermDebtAndCapitalSecurities
|
11704000 | |
CY2016Q1 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
6000 | |
CY2015Q1 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
11000 | |
CY2016Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
165000 | |
CY2015Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
3932000 | |
CY2016Q1 | us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
-6136000 | |
CY2015Q1 | us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
2554000 | |
CY2014Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
36431000 | |
CY2015Q1 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
38985000 | |
CY2016Q1 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<div> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of unaudited condensed financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities and the reported amounts of revenues and expenses in the unaudited condensed financial statements and accompanying notes. On an ongoing basis, management evaluates its estimates, including those related to (i) revenue recognition, (ii) the differences between amounts billed and estimated receipts from payers, (iii) the determination of the accruals for clinical studies, (iv) the determination of refunds to be requested by third-party payers, (v) the fair value of assets and liabilities, (vi) the valuation of warrants to purchase common stock, (vii) the fair value of contingent consideration in a business acquisition, (viii) the fair value of embedded derivatives, (ix) measurement of stock-based compensation expense, (x) the determination of the valuation allowance and estimated tax benefit associated with deferred tax assets and net deferred tax liability, (xi) any impairment of long-lived assets including in-process technology and goodwill and (xii) legal contingencies. Actual results could differ from those estimates.</p></div> | |
CY2016Q1 | us-gaap |
Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
|
<div> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Concentrations of Credit Risk and Other Risks and Uncertainties</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to credit risk consist of cash and cash equivalents and accounts receivable. The Company’s policy is to invest its cash and cash equivalents in money market funds, obligations of U.S. government agencies and government-sponsored entities, commercial paper, and various bank deposit accounts. These financial instruments were held in Company accounts at two financial institutions. The counterparties to the agreements relating to the Company’s investments consist of financial institutions of high credit standing. The Company is exposed to credit risk in the event of default by the financial institutions to the extent of amounts recorded on the balance sheets which may be in excess of insured limits.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is also subject to credit risk from its accounts receivable which are derived from revenue earned from AlloMap tests provided for patients located in the U.S. and billed to various third-party payers. <font style="color:#000000;">The Company has not experienced any significant credit losses and does not generally require collateral on receivables. </font>For the three months ended March 31, 2016 and 2015, approximately 47%, and 52%, respectively, of testing revenue was derived from Medicare. No other payers represented more than 10% of testing revenue for these periods. At March 31, 2016, Medicare, Aetna and Humana accounted for approximately 30%, 21% and 11% of accounts receivable, respectively. At December 31, 2015, Medicare and Aetna accounted for approximately 35% and 21% of accounts receivable, respectively. No other payers represented more than 10% of accounts receivable at March 31, 2016 and December 31, 2015. </p></div> | |
CY2016Q1 | us-gaap |
Goodwill Impairment Loss
GoodwillImpairmentLoss
|
0 | |
CY2016Q1 | cdna |
Fair Value Measurements Inter Transfers Between Levels
FairValueMeasurementsInterTransfersBetweenLevels
|
0 | |
CY2016Q1 | us-gaap |
Revenue Recognition Multiple Element Arrangements
RevenueRecognitionMultipleElementArrangements
|
<div> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Collaboration, License and Other Revenue</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company generates revenue from collaboration and license agreements. Collaboration and license agreements may include non-refundable upfront payments, partial or complete reimbursement of research and development costs, contingent payments based on the occurrence of specified events under the agreements, license fees and royalties on sales of products or product candidates if they are successfully commercialized. The Company’s performance obligations under the collaborations may include the transfer of intellectual property rights in the form of licenses, obligations to provide research and development services and obligations to participate on certain development committees with the collaboration partners. The Company makes judgments that affect the periods over which it recognizes revenue. The Company periodically reviews its estimated periods of performance based on the progress under each arrangement and accounts for the impact of any change in estimated periods of performance on a prospective basis.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes contingent consideration received from the achievement of a substantive milestone in its entirety in the period in which the milestone is achieved, which the Company believes is consistent with the substance of its performance under its various license and collaboration agreements. The Company did not recognize any milestones during the three months ended March 31, 2016 and 2015.</p></div> | |
CY2015Q4 | cdna |
Accrued Clinical And Cost Of Other Studies Current
AccruedClinicalAndCostOfOtherStudiesCurrent
|
756000 | |
CY2016Q1 | us-gaap |
Deferred Rent Credit Current
DeferredRentCreditCurrent
|
272000 | |
CY2016Q1 | us-gaap |
Revenue Recognition Milestone Method Revenue Recognized
RevenueRecognitionMilestoneMethodRevenueRecognized
|
0 | |
CY2015Q1 | us-gaap |
Revenue Recognition Milestone Method Revenue Recognized
RevenueRecognitionMilestoneMethodRevenueRecognized
|
0 | |
CY2016Q1 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
286000 | |
CY2015Q4 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
89000 | |
CY2016Q1 | cdna |
Accrued Sample Processing Fees
AccruedSampleProcessingFees
|
451000 | |
CY2015Q4 | us-gaap |
Deferred Rent Credit Current
DeferredRentCreditCurrent
|
258000 | |
CY2016Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
2340464 | |
CY2016Q1 | us-gaap |
Number Of Operating Segments
NumberOfOperatingSegments
|
1 | |
CY2016Q1 | us-gaap |
Debt And Capital Lease Obligations
DebtAndCapitalLeaseObligations
|
15900000 | |
CY2016Q1 | us-gaap |
Additional Cash And Cash Equivalent Related Text
AdditionalCashAndCashEquivalentRelatedText
|
Cash equivalents consist of short-term, highly liquid investments with original maturities of three months or less from the date of purchase. | |
CY2016Q1 | us-gaap |
Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
|
0 | |
CY2015Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
2012525 | |
CY2015Q4 | cdna |
Accrued Sample Processing Fees
AccruedSampleProcessingFees
|
426000 | |
CY2016Q1 | us-gaap |
Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
|
63000 | |
CY2016Q1 | us-gaap |
Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
|
247000 | |
CY2015Q4 | us-gaap |
Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
|
237000 | |
CY2016Q1 | us-gaap |
Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
|
348000 | |
CY2015Q4 | us-gaap |
Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
|
529000 | |
CY2016Q1 | cdna |
Accrued Debt Financing Fees Current
AccruedDebtFinancingFeesCurrent
|
1687000 | |
CY2016Q1 | cdna |
Accrued Transaction Related Fees Current
AccruedTransactionRelatedFeesCurrent
|
674000 | |
CY2015Q4 | cdna |
Accrued Transaction Related Fees Current
AccruedTransactionRelatedFeesCurrent
|
589000 | |
CY2016Q1 | cdna |
Accrued Over Payments And Refunds
AccruedOverPaymentsAndRefunds
|
212000 | |
CY2015Q4 | cdna |
Accrued Over Payments And Refunds
AccruedOverPaymentsAndRefunds
|
163000 | |
CY2016Q1 | cdna |
Accrued Clinical And Cost Of Other Studies Current
AccruedClinicalAndCostOfOtherStudiesCurrent
|
999000 | |
CY2015Q4 | us-gaap |
Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
|
71000 | |
CY2016Q1 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
654000 | |
CY2015Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
540000 | |
CY2016Q1 | cdna |
Description Of Agreement Expected Expiration Year
DescriptionOfAgreementExpectedExpirationYear
|
The agreement will expire at the later of the last-to-expire patent in the EEA or ten years from the first commercial sale of the test in the EEA, which occurred in 2014. | |
CY2013Q2 | cdna |
Potential Refundable Portion Of Upfront Payment
PotentialRefundablePortionOfUpfrontPayment
|
250000 | |
CY2013Q2 | cdna |
Potential Refundable Portion Of Upfront Payment
PotentialRefundablePortionOfUpfrontPayment
|
344000 | |
CY2013Q2 | cdna |
Upfront Payment In Cash
UpfrontPaymentInCash
|
387500 | |
CY2013Q2 | cdna |
Upfront Payment In Cash
UpfrontPaymentInCash
|
503000 | |
CY2013Q3 | us-gaap |
Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
|
467000 | |
CY2016Q1 | us-gaap |
Recognition Of Deferred Revenue
RecognitionOfDeferredRevenue
|
15000 | |
CY2015Q1 | us-gaap |
Recognition Of Deferred Revenue
RecognitionOfDeferredRevenue
|
27000 | |
CY2016Q1 | us-gaap |
Royalty Revenue
RoyaltyRevenue
|
96000 | |
CY2015Q1 | us-gaap |
Royalty Revenue
RoyaltyRevenue
|
90000 | |
CY2016Q1 | cdna |
Royalty Revenue Receivable
RoyaltyRevenueReceivable
|
0 | |
CY2015Q1 | cdna |
Royalty Revenue Receivable
RoyaltyRevenueReceivable
|
90000 | |
CY2015Q1 | us-gaap |
Line Of Credit Facility Maximum Borrowing Capacity
LineOfCreditFacilityMaximumBorrowingCapacity
|
20000000 | |
CY2016Q1 | us-gaap |
Debt Instrument Description Of Variable Rate Basis
DebtInstrumentDescriptionOfVariableRateBasis
|
Draw A bears interest at a daily floating rate equal to 2.00%, plus the greater of (i) 3.25% or (ii) the prime rate published by the lender. | |
CY2015Q1 | us-gaap |
Debt Instrument Basis Spread On Variable Rate1
DebtInstrumentBasisSpreadOnVariableRate1
|
0.0200 | |
CY2016Q1 | us-gaap |
Line Of Credit Facility Initiation Date1
LineOfCreditFacilityInitiationDate1
|
2015-01-30 | |
CY2016Q1 | us-gaap |
Debt Instrument Maturity Date
DebtInstrumentMaturityDate
|
2018-12-01 | |
CY2016Q1 | cdna |
Debt Issuance And Discount Component Of Recognized Debt Liability Current
DebtIssuanceAndDiscountComponentOfRecognizedDebtLiabilityCurrent
|
100000 | |
CY2015Q4 | cdna |
Debt Issuance And Discount Component Of Recognized Debt Liability Current
DebtIssuanceAndDiscountComponentOfRecognizedDebtLiabilityCurrent
|
200000 | |
CY2016Q1 | cdna |
Debt Issuance And Discount Component Of Recognized Debt Liability Non Current
DebtIssuanceAndDiscountComponentOfRecognizedDebtLiabilityNonCurrent
|
100000 | |
CY2015Q4 | cdna |
Debt Issuance And Discount Component Of Recognized Debt Liability Non Current
DebtIssuanceAndDiscountComponentOfRecognizedDebtLiabilityNonCurrent
|
100000 | |
CY2016Q1 | cdna |
Prepayment Penalty
PrepaymentPenalty
|
0.00 | |
CY2016Q1 | us-gaap |
Debt Instrument Description
DebtInstrumentDescription
|
The Company agreed to issue to the Lender warrants to purchase shares of the Company’s common stock upon the drawdown of each advance in an amount equal to 1.5% of the amount drawn, divided by the exercise price per share for that tranche. | |
CY2015Q1 | cdna |
Estimated Fair Value Of Warrants
EstimatedFairValueOfWarrants
|
90000 | |
CY2016Q1 | us-gaap |
Default Longterm Debt Description Of Violation Or Event Of Default
DefaultLongtermDebtDescriptionOfViolationOrEventOfDefault
|
Upon the occurrence of an event of default, a default interest rate of an additional 5% may be applied to the outstanding loan balances, and the lender may declare all outstanding obligations immediately due and payable and take such other actions as set forth in the Loan Agreement. | |
CY2016Q1 | cdna |
Percentage Of Default Interest Payment
PercentageOfDefaultInterestPayment
|
0.05 | |
CY2015Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
|
510892 | |
CY2016Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
|
357075 | |
CY2016Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
371970 | |
CY2016Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
|
86888 | |
CY2016Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
|
156 | |
CY2016Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
|
583041 | |
CY2015Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
1577317 | |
CY2016Q1 | cdna |
Share Based Compensation Arrangement By Share Based Payment Award Increase In Number Of Shares Reserved For Available For Issuance
ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesReservedForAvailableForIssuance
|
0 | |
CY2016Q1 | us-gaap |
Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
|
1823 | |
CY2016Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
1860420 | |
CY2015Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
6.87 | |
CY2016Q1 | cdna |
Share Based Compensation Arrangement By Share Based Payment Award Weighted Average Exercised Price Shares Reserved
ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageExercisedPriceSharesReserved
|
0 | |
CY2016Q1 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
|
5.14 | |
CY2016Q1 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
|
3.11 | |
CY2016Q1 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
|
6.08 | |
CY2016Q1 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
|
5.00 | |
CY2016Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
6.56 | |
CY2016Q1 | cdna |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingNumber
|
844288 | |
CY2016Q1 | cdna |
Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingNumber
|
1016132 | |
CY2016Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
|
1860420 | |
CY2016Q1 | cdna |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageExercisePrice
|
6.03 | |
CY2016Q1 | cdna |
Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestWeightedAverageExercisePrice
|
7.00 | |
CY2016Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
|
6.56 | |
CY2016Q1 | cdna |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested Outstanding Weighted Average Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageContractualTerm
|
P6Y9M15D | |
CY2016Q1 | cdna |
Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Outstanding Weighted Average Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingWeightedAverageContractualTerm
|
P9Y22D | |
CY2016Q1 | cdna |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Contractual Term1
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageContractualTerm1
|
P8Y11D | |
CY2016Q1 | cdna |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAggregateIntrinsicValue
|
1219000 | |
CY2016Q1 | cdna |
Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAggregateIntrinsicValue
|
141000 | |
CY2016Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
|
1360000 | |
CY2016Q1 | us-gaap |
Share Price
SharePrice
|
4.96 | |
CY2016Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
2.07 | |
CY2015Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
2.76 | |
CY2016Q1 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
|
2600000 | |
CY2016Q1 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
|
P2Y8M19D | |
CY2016Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0.00 | |
CY2015Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0.00 | |
CY2016Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
446000 | |
CY2015Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
280000 | |
CY2016Q1 | us-gaap |
Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
|
0 | |
CY2016Q1 | us-gaap |
Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
|
0 | |
CY2016Q1 | us-gaap |
Payments Of Financing Costs
PaymentsOfFinancingCosts
|
2900000 | |
CY2016Q1 | cdna |
Class Of Warrant Exercisable Period
ClassOfWarrantExercisablePeriod
|
P7Y | |
CY2016Q1 | cdna |
Initial Exercise Price Of Warrants
InitialExercisePriceOfWarrants
|
4.98 | |
CY2016Q1 | cdna |
Additional Issued Units
AdditionalIssuedUnits
|
334169 | |
CY2016Q1 | cdna |
Common Stock And Warrant Issued To Purchase Of Common Share
CommonStockAndWarrantIssuedToPurchaseOfCommonShare
|
2005014 |